IRMD Iradimed Corp

IRADIMED CORPORATION Named to TIME's List of America's Growth Leaders for 2026

IRADIMED CORPORATION Named to TIME's List of America's Growth Leaders for 2026

Recognized for Exceptional Revenue Growth, Financial Stability, and Stock Performance

ORLANDO, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD), a leader in developing innovative magnetic resonance imaging (MRI)-compatible medical devices, today announced its selection to TIME's prestigious list of America's Growth Leaders for 2026. This marks the Company's recognition among the top U.S. companies demonstrating outstanding growth, as determined by TIME and Statista.

The ranking evaluated thousands of public companies across three key dimensions: Revenue Growth, Financial, and Stock Performance. Scores from these dimensions were weighted equally in a comprehensive model, with the highest-scoring 501 companies earning the distinction of "America's Growth Leaders of 2026.” Iradimed ranked 79th on the list.

“We are honored to be named to TIME's America's Growth Leaders for 2026,” said Roger Susi, President and Chief Executive Officer of Iradimed. “This recognition reflects our team's relentless commitment to innovation, operational excellence, and delivering long-term shareholder return. Our consistent revenue growth—highlighted by 17 consecutive quarters of record revenue—along with strong financial health and stock performance, underscores the success of our strategy in the MRI-compatible medical device market. We extend our deepest gratitude to our employees for their hard work and dedication, and to our shareholders for their continued support.”

For more information and the complete list, visit: .

About the Methodology

TIME and Statista evaluated U.S.-based public companies using a rigorous, data-driven approach across three equally weighted dimensions:

  • Revenue Growth: Focused on compound annual growth rate (CAGR) from 2021 to 2024, with a minimum revenue threshold.
  • Financial Stability: Analyzed profitability alongside classic metrics such as the Piotroski F-Score and Altman Z-Score.
  • Stock Performance: Assessed using multiple KPIs, including average annual growth rate, recent returns, comparison to the overall market, and volatility over the past five years.

Data was consolidated into a scoring model with a maximum of 100 points. The 501 companies with the highest scores were named America's Growth Leaders of 2026.

About IRADIMED CORPORATION

IRADIMED CORPORATION is a leader in developing innovative Magnetic Resonance Imaging (“MRI”) compatible medical devices. We design, manufacture, market, and distribute MRI-compatible medical devices, accessories, disposables, and related services.

We are the only known provider of a non-magnetic intravenous (“IV”) infusion pump system specifically designed for safe use during MRI procedures. We were the first to develop an infusion delivery system that largely eliminates many of the dangers and problems present during MRI procedures. Standard infusion pumps contain magnetic and electronic components that can cause radio-frequency interference and are dangerous to operate in the presence of the powerful magnet used in an MRI system. Our patented MRidium® MRI-compatible IV infusion pump system has a non-magnetic ultrasonic motor, uniquely designed non-ferrous parts, and other special features to safely and predictably deliver anesthesia and other IV fluids during various MRI procedures. Our pump solution provides a seamless approach that enables accurate, safe, and dependable fluid delivery before, during, and after an MRI scan, which is essential to critically ill patients who cannot be removed from their vital medications and children and infants who must generally be sedated to remain immobile during an MRI scan.

Our 3880 MRI-compatible patient vital signs monitoring system has been designed with non-magnetic components and other special features to safely and accurately monitor a patient’s vital signs during various MRI procedures. The Iradimed 3880 system operates dependably in magnetic fields up to 30,000 gauss, allowing it to operate virtually anywhere in the MRI scanner room. The Iradimed 3880 has a compact, lightweight design, allowing it to travel with the patient from the critical care unit to the MRI and back, increasing patient safety through uninterrupted vital signs monitoring and reducing the time critically ill patients are away from critical care units. The features of the Iradimed 3880 include wireless ECG with dynamic gradient filtering; wireless SpO2 using Masimo® algorithms; non-magnetic respiratory CO2; invasive and non-invasive blood pressure; patient temperature, and an optional advanced multi-gas anesthetic agent unit featuring continuous Minimum Alveolar Concentration measurements. The Iradimed 3880 MRI-compatible patient vital signs monitoring system features an easy-to-use design and enables effective communication of patient vital signs information to clinicians.

For more information, please visit .

Media Contact:

Jack Glenn

IRADIMED CORPORATION

(407) 677-8022



EN
10/11/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Iradimed Corp

 PRESS RELEASE

IRADIMED CORPORATION Named to TIME's List of America's Growth Leaders ...

IRADIMED CORPORATION Named to TIME's List of America's Growth Leaders for 2026 Recognized for Exceptional Revenue Growth, Financial Stability, and Stock Performance ORLANDO, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD), a leader in developing innovative magnetic resonance imaging (MRI)-compatible medical devices, today announced its selection to TIME's prestigious list of America's Growth Leaders for 2026. This marks the Company's recognition among the top U.S. companies demonstrating outstanding growth, as determined by TIME and Statista. The ranking eva...

Iradimed Corp: 1 director

A director at Iradimed Corp sold 5,000 shares at 82.643USD and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...

 PRESS RELEASE

IRADIMED CORPORATION Reports Record Third Quarter 2025 Financial Resul...

IRADIMED CORPORATION Reports Record Third Quarter 2025 Financial Results Announces Regular Quarterly Cash Dividend of $0.17 Per Share and Raises Full-Year Guidance Reports record revenue of $21.2 million for the third quarter of 2025, an increase of $2.9 million, or 16%, compared to the same period in 2024.Reports record GAAP diluted EPS of $0.43 and non-GAAP diluted EPS of $0.47 for the third quarter of 2025, which are increases of 8% and 9%, respectively, compared to the same period in 2024.Raises full-year guidance to revenue of $82.5 million to $83.5 million and GAAP diluted EPS to $1...

 PRESS RELEASE

IRADIMED CORPORATION to Hold Third Quarter of 2025 Financial Results C...

IRADIMED CORPORATION to Hold Third Quarter of 2025 Financial Results Conference Call on November 3, 2025 ORLANDO, Fla., Oct. 27, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2025 third quarter financial results before the market opens on Monday, November 3, 2025. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conference call may do so by registering here, . Once registered, a d...

 PRESS RELEASE

IRADIMED CORPORATION Announces Board Transition: Anthony Vuoto Retires...

IRADIMED CORPORATION Announces Board Transition: Anthony Vuoto Retires, Joe Kiani Appointed as New Director ORLANDO, Fla., Sept. 02, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (“Iradimed” or the “Company”) (NASDAQ: IRMD), a leader in innovative medical devices for Magnetic Resonance Imaging (“MRI”)-compatible patient monitoring and infusion systems, today announced a Board of Directors (the “Board”) transition. Anthony Vuoto has retired from his position as a director, effective August 27, 2025, after deciding it is time to step away following many years of dedicated service. Effective...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch